Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 4/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032874 | 0.93 | GLP1R (0.55) | CAPN1GLP1RCTSSCTSKCNR1 | |
| SCHEMBL26032556 | 0.90 | GLP1R (0.50) | GLP1RCNR1 | |
| SCHEMBL25835683 | 0.89 | GLP1R (0.59) | CAPN1GLP1RCTSSCTSKLPAR1 | |
| SCHEMBL26032865 | 0.89 | GLP1R (0.61) | CAPN1GLP1RCTSSCTSKBCHE | |
| SCHEMBL25835480 | 0.87 | CTSK (0.52) | CAPN1GLP1RCTSSCTSKBCHE | |
| SCHEMBL25835366 | 0.86 | GLP1R (0.55) | CAPN1GLP1RCTSSCTSKLPAR1 | |
| SCHEMBL26032519 | 0.86 | GLP1R (0.55) | CAPN1GLP1RCTSSCTSKLPAR1 | |
| SCHEMBL26032522 | 0.85 | CTSK (0.50) | CAPN1GLP1RCTSSCTSKBCHE | |
| SCHEMBL16853275 | 0.82 | GLP1R (0.58) | CAPN1GLP1RCTSSCTSKLPAR1 | |
| SCHEMBL20341078 | 0.82 | GLP1R (0.58) | CAPN1GLP1RCTSSCTSKLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CAPN1 3157/4885GLP1R 1985/4885CTSS 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.